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CYTOSTAT IC  GENE TRANSFER FOR 
VASCULAR PROL IFERAT IVE  D ISORDERS 
Clinically significant restenosis remains the major complication of 
all percutaneous coronary revascularization procedures, occurring 
in 30% to 50% of patients within the first 6 months after revascu- 
latization. Although a number of factors contribute to restenosis, 
smooth muscle cell migration and proliferation and extracellular 
matrix deposition appear to be important pathophysiologic mecha- 
nisms. More than 30 different drugs and devices have been used in 
an attempt to prevent restenosis. This presentation utlines recent 
progress in using cytotoxic and cytostatic gene therapy for the 
prevention of restenosis. Recent work suggests that catheter- 
mediated elivery of replication-defective ad noviruses can be used 
to efficiently transduce medial vascular smooth muscle cells 
(VSMCs) after balloon angioplasty. Replication-defective ad novi- 
ruses encoding anonphosphorylatable, constituitively active form 
of the retinoblastoma gene (AdARb) and the herpes implex virus 
thymidine kinase gene (AdvTk) were constructed. Infection of 
primary rat aortic smooth muscle cells with AdARb completely 
inhibited growth factor-stimulated VSMC proliferation i  vitro. 
More importantly, AdkRb infection of balloominjured arterial 
segments reduced restenosis by 50% to 70% in the rat carotid and 
porcine iliofemoral models of balloon angioplasty. Safety studies 
demonstrated (1) no vascular inflammation, (2) no evidence of 
distant infection with AdkRb after local catheter delivery, and (3) 
no significant abnormalities of serum chemical composition or 
clotting parameters. Finally, infection with AdARb did not inhibit 
reendothelialization of the balloon-injured vessels. In a parallel set 
of experiments, infection of primary rat aortic smooth muscle cells 
with the AdvTK vector followed by ganciclovir treatment resulted 
in the efficient killing of proliferating cultured vascular smooth 
muscle cells in vitro. More importantly, infection with this vector 
followed by systemic ganciclovir t eatment resulted in 50% to 70% 
reductions in restenosis in both the rat carotid and porcine 
iliofemoral artery models of balloon angioplasty. There were no 
local or systemic toxicities associated with AdvTk plus ganciclovir 
therapy. In summary, catheter-mediated delivery of adenovirus 
vectors represents an efficient means of delivering recombinant 
genes to vascular smooth muscle cells at the site of balloon 
angioplasty. Both cytotoxic and cytostatic genes have been used to 
significantly reduce restenosis in two animal models of balloon 
angioplasty. Gene therapy holds promise as a safe and effective 
means of inhibiting restenosis after balloon angioplasty and other 
percutaneous revascularization procedures in human beings. 
Jeffrey M. Leiden, MD, PhD 
University of Chicago 
Chicago, Ill. 
MODIF ICAT ION OF  THE VASCULAR 
PHENOTYPE BY V IRAL  GENE TRANSFER:  
THERAPY AND TOXIC ITY  
Genetic modification of the vessel wall holds promise for the study 
of vascular pathophysiology and for the therapy of vascular disease. 
Using a variety of techniques, including viral and liposome- 
mediated gene transfer, specific genes may be introduced into 
vascular smooth muscle cells or endothelial cells to modify the 
vascular phenotype. Eventually such an approach may be clinically 
applied to artery or vein grafts, mechanically denuded vessels, or 
prosthetic grafts in the operative setting to prevent hrombosis, 
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restenosis, or recurrent disease. Work in our laboratory has focused 
on using gene transfer to increase the production of fibrinolytic 
proteins by endothelial cells on seeded prosthetic grafts, and to 
locally deliver the potent hrombin inhibitor, hirudin, to the wall of  
an injured artery. 
Genetic manipulation to decrease the thrombogenicity of a 
vascular segment is an attractive goal because arly postoperative 
thrombosis  a frequent cause of arterial bypass failure. To enhance 
vascular antithrombotic a tivity, endothelial cells might be geneti- 
cafly modified to overexpress fibrinolytic molecules uch as uroki- 
nase or t-PA. Modified endothelial cells might then be used to seed 
prosthetic grafts or denuded vessel surfaces to prevent thrombotic 
complications. In addition, endothelial cells within vascular seg- 
ments may be transduced invivo or autologous vascular grafts may 
be modified ex vivo to diminish their thrombotic potential. 
In initial work we reported that retrovirus-mediated ransfer of 
t-PA or urokinase to sheep as well as nonhuman primate ndothelial 
cells in vitro resulted in increased plasminogen activator activity. 1'2 
Implantation of collagen-coated vascular graft segments eeded 
with these genetically engineered endothelial cells reduced platelet 
and fibrin deposition in a baboon model of thrombosis of an 
arteriovenous shunt) Importantly, the measured enhancement of 
local flbrinolysis occurred without an increase in systemic fibtin- 
olytic activity. 
Although autologous artery or vein is the conduit of  choice for 
peripheral and coronary artery revascularization procedures, the 
limited availability of these vessels has stimulated tremendous 
interest in the development of prosthetic grafts with equivalent 
patency rates. A potential clinical application of the vascular graft 
seeding protocol used in the baboon shunt experiment described 
above a would be to coat small-diameter p osthetic grafts with 
endothelial cells. In this manner early thrombotic occlusion might 
be prevented. Several attempts to create grafts lined with endothe- 
lial cell monolayers, however, have produced only variable success 
in improving long-term patency rates, and no success has been re- 
ported in applying seeding technology to small-diameter (<6 mm) 
prosthetic grafts. To explore the possibility that small-diameter 
graft patency rates might be improved by seeding the grafts with 
fibrinolytically "enhanced" cells, we seeded 4-mm diameter col- 
lagen-impregnated Dacron grafts with endothelial cells engineered 
to overexpress t-PA. The seeded grafts were implanted both in vitro 
in a flow simulator and in vivo as interposition grafts in the common 
femoral or common carotid arteries of sheep) Unfortunately, we 
found that endothelial cells overexpressing t-PA were retained at 
low rates both in vitro and in vivo, when compared with endothelial 
cells engineered with a marker gene, [3-galactosidase. Control 
experiments suggested that the observed low retention was due to 
increased proteolytic activity produced by the enzymatically active 
t-PA. Thus not only did t-PA promote thrombolysis, it also 
promoted cell detachment. One potential solution to this problem 
might involve the development ofa graft matrix component that is 
resistant to proteolysis, thereby improving endothelial cell reten- 
tion. Alternatively, modifying endothelial cells to produce other 
proteins such as hirudin (which inhibit thrombosis but lack 
proteolytic activity) may result in improved endothelial cell adher- 
ence to grafts while also increasing raft patency rates. These 
hypotheses await testing; at present the utility of genetic engineer- 
ing to increase small-diameter g aft patency rates remains un- 
proven. 
Retroviral vectors have been used by several groups to transfer 
genes to vascular cells in vitro. However, the utility of retroviral 
vectors for in vivo vascular gene transfer is limited, due both to low 
titers and to the inability of these vectors to transfer genes into 
nondividing cells. In contrast, adenoviral vectors are notably 
successful for in vivo vascular gene transfer.5 Adenoviral vectors may 
be propagated and concentrated to very high titers and can 
efficiently transfer genes into nondividing cells, such as the endo- 
thelial and smooth muscle cells of a quiescent artery wall. We have 
used adenoviral vectors to transfer genes to endothelial nd smooth 
muscle cells of sheep, rat, and rabbit arteries in vivo. 6-8 In vivo gene 
transfer efficiencyis reliably high: 20% to 30% of cells exposed to the 
vectors are transduced and significant quantities of recombinant 
proteins are produced in vivo after adenovirus-mediated gene 
transfer. These quantities (13 to 550 ng recombinant protein/rag 
vessel wall protein) appear adequate to alter the arterial phenotype, 
as they are comparable with levels of endogenous arterial proteins 
such as t-PA and basic fibroblast growth factor. 9Disadvantages of
adenoviral vectors include short-term gene expression and both 
acute and chronic host inflammatory esponses following adenovi- 
rus infection. Short-term expression, however, might be an advan- 
tage depending on the therapeutic goal. For example, preventing 
thrombus formation on a denuded vessel surface after endarterec- 
tomy may require only transient gene expression until reendothe~ 
lialization has taken place. Furthermore, improved adenoviral 
vectors that cause less inflammation may soon become available) ° 
After our initial dosing and toxicity studies we constructed an 
adenoviral vector capable of expressing recombinant hirudin, n
Hirudin is an extremely potent and specific inhibitor ofthrombin, 
and expressio n of hirudin in an artery wall would be expected to 
reduce local thrombin activity. Thrombin is thought o play an 
integral role in neointima formation after arterial injury, ~z and 
inhibition of thrombin by hirudin could therefore decrease neoin- 
tima formation. Local delivery ofhirudin has potential advantages 
over systemic delivery in that with local delivery, systemic antico- 
agulation and hemorrhage might be avoided. 
Adenovirus-mediated gene transfer of hirudin to balloon- 
injured carotid arteries resulted in the secretion of biologically 
active hirudin by rat vascular smooth muscle cells and decreased 
neointima formation.n Importantly, local hirudin delivery did not 
affect systemic partial thromboplastin times. This stud), demon- 
strated that in vivo gene transfer could be used to modify the local 
vascular phenotype without causing undesirable systemic effects. 
Although adenoviral vectors can efficiently transfer genes to 
the vessel wall in vivo, their utility might be limited by inflammatory 
responses evoked by adenovirus infection. Delivery of highly 
concentrated virus to the artery wall can produce both cellular 
toxicity and an acute inflammatory esponse. 7 Expression of open 
reading frames encoded within current generation adenovirus 
vectors may elicit both humoral and cellular immune responses) ° 
Because production of arterial inflammation after adenovirus- 
mediated gene transfer could create rather than ameliorate vascular 
disease, we investigated the effects of exposure of normal arteries to 
replication-defective adenovirus vectors,  Exposure of rabbit 
femoral arteries to a replication-defective adenovirus vector 
provoked: (1) a significant vascular inflammatory response char- 
acterized by pronounced T lymphocyte infiltration throughout 
the artery wall; (2) up-regulation of both ICAMq and VCAM-1 
expression by vascular smooth muscle cells; and (3) neointimal 
hyperplasia. Therefore, current adenovirus vectors are not merely 
benign delivery vehicles for the expression of transgenes in the 
arterial wall. The current utility of adenovirus vectors both for 
biologic and therapeutic studies is limited by the inflammatory 
response that results from the host response to vector proteins. 
Our laboratory is currently pursuing two approaches to 
circumvent the inflammatory esponse to adenovirus: (1) suppres- 
sion of the immune response to viral protein expression by 
immunomodulation f the host; and (2) development of new 
adenoviral vectors that are less immunogenic. We are currently 
JOURNAL OF VASCULAR SURGERY 
Volume 24, Number 1 Special Communication 165 
testing both of these approaches in our models of arterial gene 
transfer. 
In conclusion, vascular gene transfer has the potential to 
produce profound local biologic effects without perturbing sys- 
temic physiology. In this role, gene transfer may eventually become 
a clinically useful targeted therapy for specific types of vascular 
disease. In 1996, however, substantial issues of efficiency, duration 
of expression, toxicity, arid long-term efficacy remain to be ad- 
dressed. The promise of viral gene therapy in the treatment of 
vascular disease is only now beginning to be clarified. 
David Dichek, MD 
Darren B. Schneider, MD 
Kurt D. Newman, MD 
University of California, San Francisco 
Gladstone Institute of Cardiovascular Disease 
San Francisco, Calif. 
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DIRECT TRANSFER- -  
NONVIRAL  APPROACHES 
ecNOS AND INT IMAL  HYPERPLASIA  
We have adopted a broad view of gene therapy as part of the 
emerging therapeutic armamentarium of molecular medicine in 
which DNA is used as a therapeutic agent of "drug" capable of 
modifying biologic or pathologic processes to ameliorate the 
course of disease. Accordingly, our objectives have been (1) to use 
the technology of genetic engineering toehicid~te he ftmdamental 
molecular mechanisms of cardiovascular disease and (2) to use 
DNA transfer technology to modify these pathobiologic processes 
in an attempt to develop novel therapeutic strategies that alter the 
natural history of cardiovascular disease. 
Although there are many strategies for modifying ene expres- 
sion in the intact animal, we have used modified liposomes as 
molecular delivery systems. In particular, we have adopted the use 
of Sendal virus hemagghiting virus of Japan (HVJ) conjugated to 
liposomes as a highly efficient method for introducing expression 
vector plasmids and oligonucleotides into cardiovascular tissues. 
We have successfully used this transfeetion system to modify gene 
expression within the vasculature, the kidney, the heart, and the 
liver. The efficacy of the HVJ-liposome system as a molecular 
delivery system will be discussed. This system may serve as a 
prototype of a molecular delivery system in which the proteins 
expressed by viruses that ordinarily facilitate cellular uptake are 
separated from the viral genome and employed in artificial DNA 
delivery complexes. We have successfully used this molecular 
delivery system to modulate vascular gene expression with antigene 
strategies such as antisense oligonucleotides or transcription factor 
cis element decoys as well as gene augmentation approaches using 
plasmid expression vectors. 
Our discussion will focus on several in vivo genetic engineering 
strategies that we have used to modify cell proliferation in the 
vasculature and the kidney, which may alter the natural history of 
vascular and glomerular diseases. We are intrigued by the observa- 
tion that acute manipulation of gene expression within the vessel 
;vail that arrests cell-cycle progression has long-term consequences 
on vascular function and structure. In particular, we will highlight 
the potential use of these genetic engineering strategies to create 
bioengineered vein grafts that are resistant to atherosclerosis. In 
further characterization f this intriguing phenomenon, we have 
observed that the long-term efficacy of our genetic engineering 
strategy in conferring antiatherogenic properties to the vein grafts 
is associated with the preservation f normal endothelial function as 
evidenced by nitric oxide generation. We are currently character- 
izing the molecular basis of this phenomenon. 
Many studies have documented the association betwccn vas~ 
cular disease and endothelial dysfunction; however, it remained to 
be demonstrated whether nitric oxide is actually an endogenous 
inhibitor ofvascular lesion formation in vivo. We dircctly tested this 
hypothesis by transfecting the endothelial cell-type nitric oxide 
synthase III gene into the vessel wall after balloon angioplasty 
injury as a gene therapy strategy to prevent restenosis. These studies 
provided the first direct evidence that nitric oxide inhibits vascular 
lesion formation in vivo. 
Although there are a number of potential gene therapy 
strategies for the treatment ofvascular disease, there is compelling 
evidence that he nitric oxide genes fulfill many of the characteristics 
of an ideal candidate. An important limitation of current ap- 
proaches to modulate gene expression within the vessel wall is the 
relatively low efficiency of all of the gene transfer methods used to 
date. The majority of cells within the vessel wall fail to express the 
gene therapy target gene. Therefore, gene therapy strategies that 
